HEK293-CLDN6 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Stable (KO/Expressing) Cells |
| Tissue Type |
Transformed cell lines |
| Organism |
Human |
| Donor History |
Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Growth Properties |
Monolayer ,adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS ,1 mM sodium pyruvate ,10 mM HEPES ,1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. Dissociation reagent: Trypsin-EDTA. Seeding density: 2 to 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.
HEK293-CLDN6 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human claudin-6 (CLDN6), a tight junction-associated transmembrane protein belonging to the claudin family. CLDN6 is normally expressed during embryonic and fetal development but is largely absent in most healthy adult tissues, making it an attractive oncofetal antigen for targeted cancer therapy. Aberrant re-expression of CLDN6 has been identified in multiple malignancies, including ovarian cancer, testicular germ cell tumors, endometrial cancer, gastric cancer, and certain sarcomas. Stable HEK293-CLDN6 models provide a controlled system for studying CLDN6 biology and evaluating CLDN6-directed therapeutic approaches.
HEK293-CLDN6 cells are widely used in oncology research and drug development for characterization of monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, CAR-T cell therapies, and other engineered immune cell platforms targeting CLDN6. The stable recombinant expression system supports quantitative assessment of antigen binding affinity, receptor density, antibody internalization, epitope specificity, and target-dependent cytotoxicity. These cells are also commonly applied in flow cytometry assay development, reporter assays, high-throughput therapeutic screening, and validation of CLDN6-targeted imaging agents. Because HEK293 cells exhibit high transfection efficiency and robust protein expression, they provide a reliable platform for recombinant membrane protein production and standardized assay generation.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

